TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00992082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, ketorolac and epinephrine
Description: Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
Study: NCT02287558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study: NCT03781609

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Roller system group (RG)
Description: They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions on the roller system per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Overground group (OG)
Description: They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions overground per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Wheelchair skills group (WSG)
Description: They will receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented.
Study: NCT01864733

Intervention type: OTHER
Group type: OTHER
Intervention: Physical rehabilitation (exercise).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation (exercise).
Study: NCT04017585

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet containing gluten
Description: gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Diet containing placebo
Description: Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
Study: NCT03330808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
Study: NCT03695562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sequential drilling technique
Description: Patient with vitamin D deficiency using sequential drilling technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sequential drilling technique
Description: Patient with vitamin D deficiency using sequential drilling technique
Study: NCT00622960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-MUFA diet
Description: The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-CHO diet
Description: The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
Study: NCT01482754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)
Description: Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
Study: NCT00877877

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
Study: NCT03394092

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative measurements the changes of IgG glycosylation
Description: Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative measurements the changes of IgG glycosylation
Description: Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
Study: NCT03375801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: This will be an online tool giving evidence based information and explanation on their options.
Study: NCT04208204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: somatocognitive physiotherapy
Description: Somatocognitive physiotherapy (SCT) is a multimodal physical therapy approach that has been developed in an attempt at alleviating the burden of longstanding pain. The main foci of SCT include: (1) bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension in different situations; (2) education about the vulvodynia and factors influencing pain experience; (3) coping with emotions and thoughts related to bodily experiences; and (4) structured homework assignments promoting application of the learned techniques in daily situation and gradual exposure to activities associated with pain. An important goal of SCT is to facilitate integration of new bodily habits into the patient's daily activities. The most important learning process thus occurs in the space between the treatment sessions. The therapeutic techniques are to be rehearsed in everyday situations.
Study: NCT01358591

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High calcium milk
Description: High calcium milk (9 mg/kgBM)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Regular Milk
Study: NCT05540301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sleeper stretching
Description: Modified sleeper stretching was performed on shoulder joint to increase internal rotation range of motion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified cross-body adduction stretch
Description: Modified cross-body adduction stretching was performed on shoulder joint to increase internal rotation range of motion.
Study: NCT04109755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
Study: NCT04698720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Relaxation with Guided Imagery
Description: Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot).The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds.The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis with Guided Imagery
Description: In the beginning of the first session we apply the Eye-Roll Test for Hypnotizability of Herbert Spiegel. Each session follows the Hypnotic Protocol with the following steps:Pre-talk/Absortion/Ratification/Aliciation/Dissociation/Awakening.~The four sessions train the participants in visual, auditory and kinesthetic perception on ulcer healing. The protocol also promotes medical treatment acceptance.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Guided Imagery
Description: This placebo consists of neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends, and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, positive or negative, which occurred before patient has the current DFU. Then, the patient is asked about a number of questions regarding the chosen episode in order to promote a more detailed reconstruction of the event. The patient is asked to imagine according to the instructions given by the Psychologist. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered regarding each of the questions.
Study: NCT05735392

Intervention type: OTHER
Group type: OTHER
Intervention: Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.
Description: Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.
Study: NCT00350714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBT and BreathID
Description: 75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
Study: NCT04181580

Intervention type: DEVICE
Group type: OTHER
Intervention: Made-to-measure compression garment
Description: Made-to-measure compression garment
Study: NCT03840525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Qigong Intervention
Description: Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Qigong
Description: This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
Study: NCT02075632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alclometasone dipropionate cream
Description: Alclometasone dipropionate cream 0.05% (15 g)
Study: NCT04705415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Niclosamide is an antihelmintic with in-vitro antiviral activity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
Study: NCT02263456

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Replenine®-VF (High Purity Factor IX)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replenine®-VF (High Purity Factor IX)
Study: NCT04320511

Intervention type: DEVICE
Intervention: CT-V
Description: CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
Study: NCT04138719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + Carboplatin
Description: nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel + Epirubicin
Description: nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；
Study: NCT01483209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of botulinum toxin A
Description: One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
Study: NCT04738253

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: The ultrasound measurement s of the axillary recess capsule thickness.
Study: NCT03266939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT04479644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-198
Description: BRII-198 given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-198
Description: BRII-198 given intravenously
Study: NCT04896203

Intervention type: PROCEDURE
Intervention: rotational thromboelastometry
Description: Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.

Intervention type: PROCEDURE
Intervention: rotational thromboelastometry
Description: Viscoelastometric method useful to study the kinetics of clot formation and fibrinolysis, providing a global information of both the cellular component and the pro and anticoagulant proteins, as well as the interactions between both components.
Study: NCT06244836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a bundle of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a bundle of care
Study: NCT00914550

Intervention type: OTHER
Intervention: Procalcitonin level, caregiver informed
Description: Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
Study: NCT05135234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscular Exercise
Description: Sedentary time (muscular inactivity when sitting) will be replaced with low effort muscular activity
Study: NCT03403036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.
Study: NCT04185818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading a book
Description: Participants requested to specify usual genre of book they read.~1. Fiction~2. Non-Fiction~3. Other~4. Don't usually read a book in bed
Study: NCT01685983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
Study: NCT00657371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope Auxiliary Imaging System
Description: A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
Study: NCT02916147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT00539422

Intervention type: GENETIC
Intervention: pcr and serum markers for breast cancer
Description: DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.

Intervention type: GENETIC
Intervention: pcr and serum markers for breast cancer
Description: DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.

Intervention type: GENETIC
Intervention: pcr and serum markers for breast cancer
Description: DNA extraction and genotyping of cytochrome P450-2D6\*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
Study: NCT02768025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional & Complementary Medicine treatment
Description: Body acupuncture, Ear acupuncture and aromatic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NRT, counselling
Description: Nicotine Replacement Therapy, counselling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NRT, counselling
Description: Nicotine Replacement Therapy, counselling
Study: NCT03276949

Intervention type: DEVICE
Intervention: Blood glucose measurement
Description: Device used to measure blood glucose levels
Study: NCT04401670

Intervention type: OTHER
Group type: OTHER
Intervention: HPV screening and triage tests
Description: The participants underwent a pelvic exam to have a provider-collected sample placed in PreservCyt \[Hologic, Inc., Bedford, MA, USA\] and a visual inspection by acetic acid (VIA) by a nurse.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HPV self-sampling
Description: The participant was escorted by the nurse to a private room and given instructions on how to self-collect their sample using Just for Me sampler \[Preventive Oncology International, Cleveland, OH, USA\].
Study: NCT05239221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZP-3601
Description: Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution visually matching active medication
Study: NCT02982499

Intervention type: DEVICE
Intervention: magnetic resonance image (MRI)
Description: Radiographic imaging that takes about 30-45 minutes

Intervention type: DEVICE
Intervention: magnetic resonance image (MRI)
Description: Radiographic imaging that takes about 30-45 minutes

Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: Images taken from the back of the eye (retina)

Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: Images taken from the back of the eye (retina)
Study: NCT03770247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative celiac plexus neurolysis
Description: neurolysis of celiac plexus by intraoperative techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT guided celiac plexus neurolysis
Description: Neurolysis of celiac plexus percutaneously by CT guidance
Study: NCT02459860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment
Description: Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
Study: NCT04479644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-198
Description: BRII-198 given intravenously
Study: NCT02459860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
Study: NCT01653652

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT01815359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Optimal Surgical Debulking
Study: NCT04479644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given intravenously
Study: NCT01603381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: Behavioral management of insomnia
Study: NCT03576105

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: irrigation /sterile saline
Description: mechanical removal of bacteria with sterile saline

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: irrigation /sterile saline
Description: mechanical removal of bacteria with sterile saline

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional methylene blue as photosensitizer
Description: Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue for oral use as photosensitizer
Description: Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes